U.S. Markets close in 3 hrs 18 mins

Teleflex's New Arrow SureBlock Kit

Zacks Equity Research

Teleflex Incorporated (TFX), a global leader in medical devices used in critical care and surgery, recently launched its new Arrow SureBlock Spinal Anesthesia collection. This will enhance Teleflex’s portfolio of spinal anesthesia products released in 2009.

The new Arrow SureBlock kit is designed to meet the changing needs of the anesthesia provider. Teleflex’s latest offering under the Arrow SureBlock brand will expand its line of Anesthesia and Airway Management products in its largest segment -- Critical Care. Revenues from the Critical Care segment edged up 0.2% year over year to $254.1 million in the second quarter.

Earlier, Teleflex announced the twin acquisitions of Willemstad, Netherlands-based LMA International N.V. and LMA’s laryngeal mask supraglottic airway business from Intavent Direct Limited. The acquisitions along with the new Arrow SureBlock are expected to boost revenues of the Anesthesia and Airway Management product line.

Per management, the revamped Arrow SureBlock collection of kits will promote patient safety and reliability for anesthesiologists. The launch underlines Teleflex’s commitment to innovation and product line extension.

The Arrow SureBlock collection includes complete medication kits for spinal anesthesia which is integrated with the Sprotte spinal needle. It has been clinically testified that use of Sprotte spinal needle curtails the occurrence of postdural puncture headaches. The new line of kits will include a glass barrel syringe to positively identify and access the spinal space in a reduced time span.  

Teleflex, headquartered in Limerick, Pennsylvania, is a manufacturer and provider of medical devices used in critical care and surgery. Its move to divest OEM Orthopedic division along with the strategy of developing new, innovative products should help improve its financial performance in the long run. The company’s focus on profitable and consistent growth with new product introduction and portfolio expansion via acquisition is expected to yield results.

However, Covidien (COV), C.R. Bard (BCR) and CareFusion (CFN), which operate in similar business segments, present a tough competitive landscape for Teleflex. Additionally, the company operates in a stringent regulatory environment. The demand for its products is susceptible to healthcare reimbursement systems in the domestic as well as the international market.

Teleflex currently retains a Zacks #4 Rank, which translates into a short-term Sell rating.

Read the Full Research Report on TFX

Read the Full Research Report on BCR

Read the Full Research Report on COV

Read the Full Research Report on CFN

Zacks Investment Research

More From Zacks.com